//www.igerbera.com en - us Tue, 03 Jan 2023 00:00:00 GMT Tue, 03 Jan 2023 11:50:00 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jama/fullarticle/2800024 Tue, 03 Jan 2023 00:00:00 GMT This retrospective observational study of adults entering HIV care between 2007 and 2019 compares differences in the prescription of integrase inhibitor–containing antiretroviral therapy by patient race and ethnicity. 329 1 52 62 10.1001/jama.2022.23617 2800024 //www.igerbera.com/journals/jamacardiology/fullarticle/2800105 Wed, 28 Dec 2022 00:00:00 GMT 理解和公关edicting cardiovascular disease (CVD) risk in people living with HIV (PLHIV) is challenging. Common CVD risk factors—such as hypertension, smoking, hypercholesterolemia, and diabetes—have established and readily modeled effects on CVD risk based on a half century of observational data. By comparison, statistically modeling effects of HIV on CVD risk presents complexities for reasons both biologic and epidemiologic. Biologically, diverse factors underlie HIV-associated CVD pathogenesis and progression, ranging from immunologic alterations favoring unresolving inflammation to harmful changes in lipid metabolism. These biological factors are not readily reduced to a singular unified mechanistic pathway and may vary considerably among PLHIV depending on virus- and host-related considerations. Epidemiologically, the evolution of HIV and antiretroviral therapy (ART) complicate longitudinal modeling of HIV as a CVD risk enhancer: approaches to HIV therapy have evolved considerably over the past 30 years, with time-varying implications for CD4+ T-cell loss/nonrecovery, nonresolving inflammation, and cumulative ART toxicities depending on the era of HIV diagnosis. Given clinical and immunologic heterogeneity among PLHIV, dichotomous approaches simply considering HIV as present or absent in CVD risk assessments inadequately capture the diverse, evolving biology of HIV-associated CVDs. 10.1001/jamacardio.2022.4880 2800105 //www.igerbera.com/journals/jamacardiology/fullarticle/2800100 Wed, 28 Dec 2022 00:00:00 GMT This systematic review and meta-analysis investigates the performance of HIV-specific and general population cardiovascular disease risk prediction models in people with HIV. 10.1001/jamacardio.2022.4873 2800100

map